CD8A and neoplasm: Recent works have demonstrated that vaccines stimulating cDC1 can induce effective anti-tumor CD8 T cell responses and that cDC1 are critical for the formation of robust tissue-resident memory T (TRM) cell responses in the skin after vaccinia virus infection, making these DC potential targets for future vaccine development (56, 57).